SIRT2, in particular, has been shown to deacetylase BARD1 at conserved lysine residues within the RING domain, promoting stability of the BRCA1-BARD1 complex and enabling tumor-suppressive function [85]. This evidence concerns the gene BRCA1 and neoplasm.